SCHEMBL14014137

SCHEMBL14014137

Cc1ccc(NS(=O)(=O)c2ccc(-c3ccccn3)s2)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.62
RXFP1 Q9HBX9 1/20 0.58
GHSR Q92847 6/20 0.54
ALDH1A1 P00352 1/20 0.50
MLNR O43193 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
DRD3 P35462 1/20 0.49
HTR6 P50406 1/20 0.49
GABRA1 P14867 1/20 0.49
POLB P06746 2/20 0.47
PKM P14618 1/20 0.46
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 2/20 0.46
GLA P06280 2/20 0.46
MAPT P10636 2/20 0.46
RAB9A P51151 2/20 0.46
CNKSR1 Q969H4 2/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7799532 0.83 PFKFB3 (0.70) PFKFB3RXFP1GHSRMLNRCYP2D6
SCHEMBL15480562 0.82 PFKFB3 (0.65) PFKFB3RXFP1GHSRALDH1A1MLNR
SCHEMBL12334571 0.81 RXFP1 (0.57) PFKFB3RXFP1GHSRMLNRCYP2D6
SCHEMBL8213512 0.80 RXFP1 (0.59) PFKFB3RXFP1GHSRPKMKDM4E
SCHEMBL12335544 0.80 RXFP1 (0.59) PFKFB3RXFP1GHSRMLNRCYP2D6
SCHEMBL5230563 0.78 RXFP1 (0.66) PFKFB3RXFP1GHSRMLNRCYP2D6
SCHEMBL2835960 0.77 PFKFB3 (0.60) PFKFB3RXFP1GHSRPKMKDM4E
SCHEMBL7909167 0.77 PFKFB3 (0.56) PFKFB3RXFP1GHSRPKMKDM4E
SCHEMBL13892314 0.77 RXFP1 (0.55) PFKFB3RXFP1GHSRALDH1A1PKM
SCHEMBL788488 0.77 PFKFB3 (1.00) PFKFB3RXFP1GHSRMLNRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR PFKFB3 860/4885RXFP1 3121/4885GHSR 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.